PSYCHOGENICS INC

Their core work

PsychoGenics is a US-based contract research organization (CRO) specializing in preclinical CNS drug discovery, with a core focus on behavioral phenotyping and quantitative biology applied to psychiatric and neurological disorders. Their real-world work involves developing and running animal model assays that bridge preclinical findings to clinical outcomes — particularly for conditions like schizophrenia, Alzheimer's disease, and major depression. In European consortia, they serve as the preclinical translational arm, contributing proprietary phenotyping platforms and data expertise that academic and pharmaceutical partners typically cannot provide in-house. Their presence in IMI2-funded work signals a recognized role in industry-relevant, clinically-anchored neuroscience research.

What they specialise in

How they've shifted over time

In their first H2020 engagement (EQIPD, 2017–2021), PsychoGenics focused on the infrastructure layer of preclinical research — data quality, reproducibility, and standardization of experimental methods. Their second project (PRISM 2, 2021–2024) represents a clear pivot toward disease-specific translational science: psychiatric biomarkers, patient stratification, and transdiagnostic methods that span multiple CNS conditions simultaneously. The trajectory points from "how do we make preclinical data reliable" toward "how do we use that reliable data to identify biomarkers that predict clinical outcomes in humans."

PsychoGenics is moving deeper into translational biomarker science, making them an increasingly relevant partner for consortia building the preclinical-to-clinical bridge in CNS drug development — especially IMI-style public-private initiatives targeting patient stratification.

How they like to work

PsychoGenics has participated in every H2020 project as a specialist contributor, never taking the coordinator role — consistent with a CRO that brings a defined, proprietary toolkit rather than consortium-building infrastructure. Despite this, they operate in large, multi-partner consortia: 42 unique partners across 11 countries from just two projects, which is an unusually high network density for an SME. This suggests they are sought-after nodes in big IMI and RIA consortia rather than initiators of collaborations.

With 42 unique consortium partners across 11 countries from only two projects, PsychoGenics punches well above its weight in network density — a direct result of participating in large IMI2 and RIA consortia that typically include 20+ organizations each. Their network spans Europe and the US, with a strong pharmaceutical industry component given the IMI2 funding context.

What sets them apart

PsychoGenics is one of very few US-based CROs with a track record of sustained participation in EU-funded neuroscience consortia, which is rare and practically valuable for European project builders who need access to American preclinical expertise and platforms without the overhead of a transatlantic subcontracting arrangement. Their combination of proprietary behavioral phenotyping technology and quantitative biology methods positions them as a provider of capabilities that are difficult to replicate within purely academic European partners. The IMI2 participation further validates their fit for industry-grade, regulatory-pathway-aware preclinical work.

Highlights from their portfolio

• PRISM 2
  An IMI2-funded project targeting transdiagnostic psychiatric biomarkers across three major CNS conditions simultaneously — one of the most ambitious patient stratification efforts in European psychiatric research, making it the project where PsychoGenics' translational expertise is most directly on show.
• EQIPD
  A pan-European initiative to reform preclinical data quality standards, notable because PsychoGenics' inclusion as a practicing CRO — rather than an academic institution — reflects their role as a real-world practitioner whose methods were relevant to setting industry benchmarks.